Bifogade filer
NET ASSET VALUE – 30 April 2026
2026-05-05 08:00:00
On the 30 April 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,478 million and NAV per share was SEK 41.79. Return on NAV per share in the month was -0.26%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 4.18 | 10.0% |
| Prokarium | 50% | 280 | 3.36 | 8.0% |
| Xspray Pharma | 17% | 217 | 2.60 | 6.2% |
| Empros Pharma | 79% | 204 | 2.46 | 5.9% |
| KAHR Medical | 34% | 199 | 2.39 | 5.7% |
| Atrogi | 44% | 197 | 2.37 | 5.7% |
| Bonsai Biotherapeutics | 100% | 158 | 1.90 | 4.5% |
| Microbiotica | 10% | 125 | 1.51 | 3.6% |
| Xintela | 60% | 122 | 1.47 | 3.5% |
| AnaCardio | 13% | 79 | 0.95 | 2.3% |
| Mendus | 23% | 69 | 0.82 | 2.0% |
| Geneos Therapeutics | 12% | 66 | 0.80 | 1.9% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.65 | 1.5% |
| Vitara Biomedical | 11% | 52 | 0.63 | 1.5% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.40 | 1.0% |
| Egetis Therapeutics | 1% | 27 | 0.33 | 0.8% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.3% |
| Strike Pharma | 18% | 11 | 0.13 | 0.3% |
| Total | 2,253 | 27.07 | 64.8% | |
| Commercial Growth | ||||
| Symcel | 30% | 204 | 2.46 | 5.9% |
| NorthX Biologics | 61% | 202 | 2.43 | 5.8% |
| Chromafora | 28% | 137 | 1.65 | 4.0% |
| Nanologica | 50% | 86 | 1.03 | 2.5% |
| Frontier Biosolutions | 2% | 26 | 0.31 | 0.8% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 656 | 7.88 | 18.9% | |
| Assets related to Portfolio companies | 204 | 2.45 | 5.9% | |
| Other assets and liabilities | 365 | 4.39 | 10.5% | |
| Net Asset Value | 3,478 | 41.79 | 100.0% | |